Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

China · Delayed Price · Currency is CNY

19.68

-0.44 (-2.19%)

Sep 11, 2026, 3:04 PM CST

SHE:300204 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Revenue	187.53	220.23	324.82	364.18	548.99	584.29
Revenue Growth	-30.03%	-32.20%	-10.81%	-33.66%	-6.04%	37.41%
Gross Profit	140.15	169.95	262.55	289.57	447.22	467.86
Operating Income	-86.42	-83.18	-44.31	-373.86	-233.87	-239.51
Net Income	-89.9	-77.76	-144.84	-398.89	-197.01	-137.4
Earnings Per Share	-0.19	-0.16	-0.30	-0.84	-0.41	-0.29
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Cash & Investments	126.16	123.64	53.91	85.18	264.99	466.47
Total Debt	162.71	93.36	42.54	40.95	28.96	7.63
Net Cash (Debt)	-36.55	30.28	11.37	44.23	236.03	458.84
Net Cash Growth	-	166.24%	-74.28%	-81.26%	-48.56%	-31.98%
Net Cash Per Share	-0.08	0.06	0.02	0.09	0.49	0.97

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Operating Cash Flow	-96.48	-125.68	-63.68	-228.32	-175.6	-162.07
Capital Expenditures	-97.02	-76.63	-23.53	-32.15	-56.51	-56.24
Free Cash Flow	-193.5	-202.31	-87.21	-260.47	-232.12	-218.31
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Gross Margin	74.73%	77.17%	80.83%	79.52%	81.46%	80.07%
Operating Margin	-46.08%	-37.77%	-13.64%	-102.66%	-42.60%	-40.99%
Pretax Margin	-52.27%	-40.10%	-10.56%	-100.62%	-44.28%	-36.45%
Profit Margin	-47.94%	-35.31%	-44.59%	-109.53%	-35.89%	-23.52%
FCF Margin	-103.18%	-91.86%	-26.85%	-71.52%	-42.28%	-37.36%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Forward PE	-	16.49	16.49	16.49	16.49	16.49
PS Ratio	50.14	59.27	10.90	13.33	11.69	14.11